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calciﬁc aortic valve disease (CAVD).Background CAVD is a chronic disorder characterized by pathological mineralization and remodeling. Studies have indicated that
human CAVD tissues are inﬁltrated by lipids and that inﬂammation may play a role in the pathobiology. We
hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAVD and may play a role in the
mineralization of valve interstitial cells.Methods We have documented the expression of the phospholipase A2 family of genes in aortic valves by using
a transcriptomic assay. Messenger ribonucleic acid and protein expression were conﬁrmed in aortic valves explanted
from 60 patients by quantitative polymerase chain reaction and immunohistochemistry, respectively. The effect of
lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization of valve interstitial
cell cultures.Results Transcriptomic analyses of CAVD and control nonmineralized aortic valves revealed that Lp-PLA2 was increased by
4.2-fold in mineralized aortic valves. Higher expression of Lp-PLA2 in stenotic aortic valves was conﬁrmed by
quantitative polymerase chain reaction, immunohistochemistry, and enzymatic Lp-PLA2 activity. The number of
Lp-PLA2 transcripts correlated with several indexes of tissue remodeling. In vitro, lysophosphatidylcholine increased
the expression of alkaline phosphatase, the ectonucleotide pyrophosphatase/phosphodiesterase 1 enzyme,
sodium-dependent phosphate cotransporter 1 (encoded by the SLC20A1 gene), and osteopontin. We then showed
that lysophosphatidylcholine-induced mineralization involved ectonucleotidase enzyme as well as apoptosis through
a protein-kinase-A-dependent pathway.Conclusions Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role in the
mineralization of valve interstitial cells. Further work is necessary to document whether Lp-PLA2 could be
considered as a novel target in CAVD. (J Am Coll Cardiol 2014;63:460–9) ª 2014 by the American College of
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A2 (encoded by PLA2G7
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VIC = valve interstitial cells
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461the sn-2 ester bond of phospholipids and generate
free fatty acids and lysophosphatidylcholine (LPC),
which, in turn, modulate inﬂammation (4,5). Recently,
LPC has been shown to promote mineralization of
vascular smooth muscle cells (6). However, the mechanism
whereby LPC promotes mineralization has not yet been
clearly elucidated.
Pathological mineralization of valve interstitial cells
(VIC), the main cellular component of the aortic valve,
relies on the expression of ectonucleotidases, membrane-
bound enzymes, that regulate the amount of nucleotides,
inorganic phosphate (Pi), and inorganic pyrophosphate
(PPi) (7). Pi-mediated mineralization and expression of
ectonucleotidases, such as ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1) and alkaline phosphatase
(ALP), relies on the protein kinase A (PKA) pathway (8). In
this work, we hypothesized that the PLA2 (PLA2G) family
of genes is differentially regulated in human CAVD tissues
and is associated with the remodeling and mineralization
of the aortic valve.
Methods
Patients. We examined 40 aortic valves that were explanted
from patients at the time of aortic valve replacement for
CAVD. Control noncalciﬁed aortic valves (n ¼ 20) with
normal echocardiographic analyses were obtained during
heart transplant procedures. Patients with a history of rheu-
matic disease, endocarditis, and inﬂammatory diseases were
excluded. Valves with moderate to severe aortic valve regur-
gitation (grade >2) were excluded. Patients with reduced left
ventricular ejection fraction (<40%) were also excluded to
eliminate potential patients with low-ﬂow, low-gradient
aortic stenosis in whom correlations with the gradient would
not be reliable. All patients underwent a comprehensive
Doppler echocardiographic examination pre-operatively.
Doppler echocardiographic measurements were performed,
including the left ventricular stroke volume and transvalvular
gradients, using the modiﬁed Bernoulli equation. The
protocol was approved by the local ethical committee, and
informed consent was obtained from the subjects.
Tissue processing, microarray, and experiments. See the
Supplemental Methods section in the Online Appendix.
Results
Transcriptomic of phospholipase A2 genes in calciﬁc
aortic valves. A tissue-based microarray experiment
was conducted to explore the gene expression pattern of
phospholipase A2 (PLA2/PLA2G) family of genes. Two
control valves failed quality control and were discarded from
subsequent analyses. Figure 1A shows a heat map of
normalized expression values for PLA2/PLA2G genes for
each sample. Fifteen probe sets were available to study the
expression of PLA2G3, PLA2G4A, PLA2G5, PLA2G6,
PLA2G7, PLA2G10, PLA2G12A, and PLA2G12B genes.
The expression of PLA2G4A and PLA2G5 was signiﬁcantlydown-regulated in stenotic valves.
In contrast, the expression of
PLA2G7 (lipoprotein-associated
phospholipase A2 [Lp-PLA2])
was increased by 4.2-fold in
stenotic aortic valves (Fig. 1A).
PLA2G4A and PLA2G5, respec-
tively, are cytosolic and secreted
enzymes that hydrolyze mem-
brane phospholipids.On the other
hand, Lp-PLA2 (PLA2G7) is
a cellular enzyme that is also
secreted, which can metabolize
oxidized low-density lipoprotein
(ox-LDL) into LPC, a powerful
inﬂammatory metabolite. The
result of the microarray experi-
ment was then conﬁrmed with
quantitative polymerase chain
reaction analyses in a larger group
of patients (Table 1). Compared
with control noncalciﬁed aortic
valves, the amount of Lp-PLA2
transcript was increased in ste-
notic aortic valves by 2.3-fold
(Fig. 1B). Considering the age
differences between patients
with CAVD and control subjects, we have repeated the
analyses after matching 20 patients for age (1 year)
(Table 2). In this analysis, we found in age-matched
groups that patients with CAVD, when compared with
control subjects, had a 3.5-fold increase in messenger
ribonucleic acid encoding for Lp-PLA2 (control: 15.3 
3.9 copies/cyclophilin A vs. CAVD: 53.6  17.0 copies/
cyclophilin A; p ¼ 0.03). Similarly, the activity of the
Lp-PLA2 enzyme was increased by 1.9-fold in stenotic
aortic valve tissues versus control nonmineralized valves
(Fig. 1C). Within the blood plasma, the activity of
Lp-PLA2 was signiﬁcantly elevated in CAVD patients
versus control subjects (Fig. 1D). In the age-matched
subjects, the plasma Lp-PLA2 activity was also signiﬁ-
cantly elevated in patients with CAVD (control: 25.7  1.6
nmol/min/ml vs. CAVD 33.7  1.6 nmol/min/ml;
p ¼ 0.001). However, enzyme activity in aortic valve and
blood plasma did not correlate signiﬁcantly (r ¼ 0.10;
p ¼ 0.75). We then documented by thin layer chromatog-
raphy that LPC, the product of Lp-PLA2 activity, is
present in stenotic valves (mean concentration: 177  23
ng/g of tissue) (Fig. 1E).
Relationships between the expression of Lp-PLA2 and
ox-LDL. Immunohistochemistry studies conﬁrmed a higher
expression of Lp-PLA2 within stenotic valves (Figs. 2A
and 2B). We found that immunostaining of Lp-PLA2
in control nonmineralized aortic valves was faint or non-
detectable (Fig. 2A), whereas there was a strong staining
in stenotic aortic valves (Figs. 2B and 2C). Two distinct
Figure 1 Expression of Lp-PLA2 in CAVD
(A) Gene expression proﬁles of the phospholipase A2 (PLA2)/PLA2G family of genes in control, noncalciﬁed aortic valves (VAHN21, VAHN24, and VAHN47) and stenotic aortic
valves (VAHC79, VAHC8, VAHC220, VAHC147, and VAHC15). Each row represents a different probe set tagging a speciﬁc enzyme, indicated at the right. The fold-change
comparing the expression of calciﬁc aortic valve disease (CAVD) versus control, noncalciﬁed aortic valves is indicated in parentheses. The asterisks represent probe sets that
are signiﬁcant based on the whole microarray experiment. (B, C) In a larger group of patients both the number of lipoprotein-associated phospholipase A2 ([Lp-PLA2] encoded by
the PLA2G7 gene) transcripts and enzyme activity were increased in CAVD tissues versus tissues from control valves. (D) Lp-PLA2 activity was increased in the blood plasma of
subjects with CAVD. (E) A thin layer chromatography showed the presence of lysophosphatidylcholine (LPC) in CAVD valves (VAHC1-3). CycloA ¼ cyclophilin A.
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462patterns of expression were observed for Lp-PLA2 in
stenotic valves. First, Lp-PLA2 was expressed in cellular-
rich inﬂammatory inﬁltrates, which are abundant in areas
of tissue remodeling and mineralization (Fig. 2B). Second,
Lp-PLA2 expression appeared as a diffuse immuno-
staining (Fig. 2C), which colocalized with ox-LDL
(Fig. 2D). Ox-LDL is a powerful promoter of Lp-
PLA2 expression as well as a substrate for the enzyme.
We then measured the blood proﬁle of patients and
correlated the results with the amount of Lp-PLA2
transcript within the aortic valve. Among the different
blood lipid variables, the number of Lp-PLA2 transcripts
within stenotic aortic valves signiﬁcantly correlated with
the blood plasma level of ox-LDL (r ¼ 0.33; p ¼ 0.01)and low-density lipoprotein (LDL) levels (r ¼ 0.29;
p ¼ 0.02) (Table 3).
Expression of Lp-PLA2 within the aortic valve is related
to tissue remodeling and the hemodynamic severity of
aortic stenosis. We next documented the relationships
between Lp-PLA2 and indexes of CAVD disease activity
and severity. The number of Lp-PLA2 transcripts increased
with the severity of the remodeling score of stenotic aortic
valves (p analysis of variance ¼ 0.002) (Fig. 3A). Also, the
number of Lp-PLA2 transcripts correlated with the weight
of the aortic valve, a marker of active remodeling that is also
related to the severity of aortic stenosis (r¼ 0.56; p¼ 0.0009)
(Fig. 3B). In addition, the level of Lp-PLA2 transcripts also
correlated with the peak transaortic gradient (r ¼ 0.56;
Table 2 Clinical Characteristics of Age-Matched Patients
Control Valves CAVD p Value
Age, yrs 52  2 53  3 NS
Male 70 70 NS
Smoking 10 20 NS
Hypertension 30 40 NS
Diabetes 10 0 NS
Coronary heart disease 70 20 0.02
Bicuspid aortic valves 0 70 <0.0001
BMI, kg/m2 27.2  1.5 25.8  0.9 NS
Statins 80 30 0.07
Ang II receptor blockers 10 20 NS
Aortic valve area, cm2 d 0.80  0.10 d
Aortic mean gradient, mm Hg d 46  3 d
Triglycerides, mmol/l 1.32  0.16 1.60  0.27 NS
LDL, mmol/l 2.36  0.25 2.42  0.29 NS
HDL, mmol/l 1.55  0.34 1.31  0.13 NS
Creatinine, mmol/l 90.3  8.7 84.4  7.6 NS
Creatinine clearance, ml/min 88.8  8.0 87.5  8.4 NS
Values are mean  SD or %.
Abbreviations as in Table 1.
Table 1 Clinical Characteristics of Patients
Control Valves CAVD p Value
Age, yrs 51  3 70  1 <0.0001
Male 78 56 NS
Smoking 11 7 NS
Hypertension 33 67 0.04
Diabetes 11 26 NS
Coronary heart disease 64 49 0.01
Bicuspid aortic valves 0 30 <0.0001
BMI, kg/m2 27.9  1.5 27.6  0.5 NS
Statins 73 61 NS
Ang II receptor blockers 11 16 NS
Aortic valve area, cm2 d 0.77  0.03 d
Aortic mean gradient, mm Hg d 43  2 d
Triglycerides, mmol/l 1.39  0.15 1.40  0.08 NS
LDL, mmol/l 2.42  0.28 2.26  0.12 NS
HDL, mmol/l 1.66  0.37 1.33  0.04 NS
Creatinine, mmol/l 92.2  9.5 92.2  3.42 NS
Creatinine clearance, ml/min 88.7  9.05 63.1  2.8 0.01
Values are mean  SD or %.
Ang II ¼ angiotensin II; BMI ¼ body mass index; CAVD ¼ calciﬁc aortic valve disease; HDL ¼ high-
density lipoprotein; LDL ¼ low-density lipoprotein; NS ¼ not signiﬁcant.
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463p ¼ 0.0004) (Fig. 3C). In the same line, the level of
messenger ribonucleic acid transcript encoding Lp-PLA2
was signiﬁcantly correlated with the amount of calcium
measured within CAVD valves (r ¼ 0.27; p ¼ 0.03).
However, the enzymatic activity of Lp-PLA2 in CAVDFigure 2 Immunodetection of Lp-PLA2 and Ox-LDL
Immunohistochemistry studies showed that in control nonmineralized aortic valves (A), Lp-
appears as cellular marking (arrows) (B) or as a diffuse staining (arrows) (C). In areas
(arrows) (D). Abbreviations as in Figure 1.tissues had a better correlation with the concentration of
calcium (r ¼ 0.56; p ¼ 0.01) (Fig. 3D).
Lysophosphatidylcholine induces mineralization of the
aortic valve through a PKA pathway. LPC is among the
main products derived from ox-LDL, following the actionPLA2 was not expressed, whereas there was a strong immunostaining in CAVD, which
of diffuse staining, Lp-PLA2 colocalized with oxidized low-density lipoprotein (ox-LDL)
Table 3
Correlation Matrix Between the Number of
Lp-PLA2 Transcripts and Clinical Data
Variables R p Value
Age 0.22 0.09
Cholesterol 0.26 0.04
LDL 0.29 0.02
HDL 0.03 0.79
Triglycerides 0.04 0.74
ox-LDL 0.33 0.01
Lp-PLA2 ¼ lipoprotein-associated phospholipase A2; ox-LDL ¼ oxidized low-density lipoprotein;
other abbreviations as in Table 1.
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464of Lp-PLA2, and present within CAVD tissues. We tested
the effect of LPC on the mineralization of VIC cultures.
We found that a small amount of LPC (1 nmol/l) increased
mineralization of VIC cultures treated with the mineralizing
medium (PO4) (Fig. 4A). LPC is normally bound to lipo-
proteins and its content is elevated in ox-LDL (9).
Furthermore, it has been shown that the high content of
LPC in ox-LDL is largely dependent on Lp-PLA2 activity
(10). We thus treated VIC with ox-LDL. In this experi-
ment, similarly to LPC, ox-LDL increased mineralization of
VIC treated with the mineralizing medium by 2.6-fold
(Fig. 4B). In isolated VIC, LPC elevated the expression of
ENPP1, ALP, the sodium-dependent phosphate cotrans-
porter-1 ([Pit-1] encoded by the SLC20A1 gene), andFigure 3 Lp-PLA2 and Indexes of CAVD Severity
(A) The number of Lp-PLA2 transcripts in CAVD valves increased signiﬁcantly with the sev
Lp-PLA2 transcripts has been log transformed). The number of Lp-PLA2 transcripts in CAV
transaortic gradient (C) (Spearman correlation). Within CAVD valves, enzyme activity of Lp
*p < 0.05 compared with remodeling score 2; #p < 0.05 compared with remodeling scoosteopontin (OPN) (Fig. 4C). The enzyme activity of ALP
and ENPP1 were also increased following a treatment of
VIC cultures with LPC (1 nmol/l) (Figs. 4D and 4E). We
have previously shown that a high expression of the ecto-
nucleotidase enzymes contribute to the mineralization
of VIC cultures by elevating phosphate levels, whereby
apoptosis-mediated mineralization is promoted. We then
treated VIC cultures with ARL67156, an ectonucleotidase
inhibitor. ARL67156 is an inhibitor of ENPP1, ENTPD1,
and ENTPD3, and only ENPP1 is expressed signiﬁcantly
by human VIC (7). In this experiment, ARL67156 pre-
vented the mineralization induced by the mineralizing
medium and LPC (Fig. 4F), suggesting that LPC-mediated
mineralization relies on the expression of ENPP1, which, in
turn, promotes mineralization. We then hypothesized that
apoptosis might be implicated in LPC-induced minerali-
zation. First, by using the detection of activated caspase 3/7
assay, we found that LPC induced the activation of the
effector caspases (Fig. 5A). Also, on exposure to LPC, there
was a loss of the mitochondrial membrane potential in the
VIC culture, indicating that the mitochondrial-dependent
pathway is involved in LPC-mediated apoptosis (Figs. 5B
and 5C). Correspondingly, we found that LPC promoted
cytochrome c release within the cytosol of VIC (Fig. 5D).
To further document the role of apoptosis in LPC-mediated
mineralization of VIC, we have used the general caspaseerity of the remodeling score of the aortic valve (to stabilize variances, the number of
D valves correlated signiﬁcantly with the weight of the aortic valve (B) and the peak
-PLA2 correlated signiﬁcantly with the amount of calcium (Spearman correlation) (D).
re 3. ANOVA ¼ analysis of variance; other abbreviations as in Figure 1.
Figure 4 LPC Induces Mineralization of VIC
(A) In isolated valve interstitial cells (VIC), LPC exacerbated the mineralization induced by phosphate (PO4). (B) In isolated VIC, medium ox-LDL exacerbated mineralization
induced by PO4. (C) In isolated VIC, exposure to LPC (1 nmol/l) increased the expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), alkaline phos-
phatase (ALP), sodium-dependent phosphate cotransporter 1 (Pit-1), and osteopontin (OPN). In isolated VIC, LPC (1 nmol/l) increased enzyme activity of both ALP (D) and ENPP
(E). (F) In isolated VIC, mineralization induced by both PO4 and LPC was abrogated by a treatment with ARL67156 (ARL), a competitive inhibitor of ectonucleotidase enzymes.
*p < 0.05 compared with control, noncalciﬁed aortic valves (Ctn); # p < 0.05 compared with mineralizing medium (PO4); yp < 0.05 compared with PO4 þ LPC. Abbreviations as
in Figures 1, 2, and 3.
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465inhibitor ZVAD-fmk. ZVAD-fmk abolished the minerali-
zation of VIC cultures induced by LPC and the calcifying
medium (Fig. 6A). Expression of ectonucleotidases and
mineralization of vascular smooth muscle cells has been
previously shown to rely on the activation of the PKA
pathway (8). Furthermore, studies have highlighted the role
of PKA in apoptosis (11). We thus hypothesized that PKA
could mediate LPC-induced mineralization of VIC cultures.
In this regard, inhibition of PKA with PKA inhibitor
fragment (6 to 22) amide prevented mineralization of VIC
cultures induced by the mineralizing medium and LPC
(Fig. 6B), suggesting that cyclic adenosine monophosphate
(cAMP)-dependent activation of PKA is involved in LPC-
mediated mineralization. LPC is a potent agonist of the G
protein-coupled receptor G2A, which may signal through
PKA (12). We have thus measured PKA activity in VIC and
found that LPC increased PKA activity by 21%. Further-
more, this effect with LPC was synergistic with the
mineralizing medium, increasing PKA activity by 40%
(Fig. 6C). To further prove the implication of the PKA
pathway in the mineralization of VIC cultures, we have
used forskolin, an agent that increases adenylate cyclase
activity and augments cell content in cAMP. To this effect,
stimulation of cAMP production with forskolin treat-
ment increased mineralization of VIC cultures inducedby mineralizing medium and LPC (Fig. 6D). We next
measured the level of cAMP in control and stenotic aortic
valves to document the activation of the cAMP pathway
in vivo. In control nonmineralized aortic valves, the amount
of cAMP was very low and beyond detection level in 5
samples, whereas it was detected in 4 stenotic aortic valves
from 5 patients (mean value 16.38  8.75 pmol/mg
protein), indicating activation of the cAMP/PKA pathway
in stenotic aortic valve tissues.Discussion
A recent report has documented that the mass of Lp-PLA2
within the blood plasma is elevated in patients with CAVD
(13). In the present study, we identiﬁed for the ﬁrst time
that Lp-PLA2 is highly expressed within stenotic aortic
valve tissues and that it contributes to valve mineralization
by the production of LPC. We next showed that
LPC-mediated mineralization of human VIC relies on
ectonucleotidase enzyme and apoptosis through a PKA
pathway.
Origin of Lp-PLA2 in CAVD. Lp-PLA2 is signiﬁcantly
expressed by platelets and macrophages. A signiﬁcant frac-
tion of Lp-PLA2 is bound to lipoproteins in the blood-
stream (14). In this work, we documented that transcripts
Figure 5 LPC Mediates Apoptosis of VIC
(A) In isolated VIC, treatment with LPC increased the activation of caspase 3/7. (B, C) In isolated VIC, LPC decreased the mitochondrial membrane potential (DJm). (D) In
isolated VIC, LPC promoted the release of cytochrome c in the cytosol. DAPI ¼ 4,6-diamino-2-phenylindole; FITC ¼ ﬂuorescein isothiocyanate; other abbreviations as in Figures 1
and 4.
Mahmut et al. JACC Vol. 63, No. 5, 2014
Lp-PLA2 and Calcific Aortic Valve Disease February 11, 2014:460–9
466encoding for Lp-PLA2 were highly expressed in CAVD
valves, indicating that the enzyme is locally synthesized.
This is in line with the immunohistochemistry studies,
which showed the expression of Lp-PLA2 by inﬂammatory
cells. However, it should be pointed out that immunohis-
tochemistry studies also showed a diffuse staining of Lp-
PLA2 in CAVD tissues, suggesting that the enzyme is
locally secreted and released by macrophages and/or trans-
ported by the lipoproteins within stenotic aortic valves.
We previously showed that the plasma level of ox-LDL is
associated with the remodeling of stenotic aortic valves (15).
In addition, we also documented that the proportion of
circulating small, dense LDL is related to the amount of ox-
LDL within CAVD tissues (2). Of interest, one study has
found that a higher proportion of Lp-PLA2 is associated
with small, dense LDL (16). Hence, it is possible that small,
dense LDL, which have a higher oxidation rate, promote the
accumulation ox-LDL, which in turn promotes the
expression of Lp-PLA2 within the aortic valve during
CAVD (17). Also, oxidized phospholipids are transported
and sequestered in the blood plasma by lipoprotein (a) (14).
To this effect, a recent work has highlighted that gene
polymorphism of lipoprotein (a) is signiﬁcantly associated
with CAVD at the genomewide level (18).Lp-PLA2–derived lysophosphatidylcholine and mineralization
of the aortic valve. In this study, the transcript levels and
enzyme activity of Lp-PLA2 correlated with several indexes of
disease activity.More speciﬁcally, the number of transcripts was
signiﬁcantly correlated with the remodeling score and the
weight of the aortic valve.Theweight of the aortic valve, a simple
and convenientmeasurement, is an independent predictor of the
hemodynamic severity of CAVD (19,20).Mineralization of the
aortic valve is certainly an important culprit, which is related to
the severity of CAVD (21). To this effect, we identiﬁed that
both the number of transcripts encoding for Lp-PLA2 and
enzyme-speciﬁc activity correlated with the amount of calcium
within CAVD. Lp-PLA2 activity better correlated (r ¼ 0.56)
with the valvular concentration of calcium than did the number
of transcripts (r ¼ 0.27). This suggests that tissue enzyme
activity, which may take into account several factors, such as the
total amount of Lp-PLA2 and differences in enzyme activity
related to the genotype, is a better correlate of pathological
mineralization of the aortic valve.
The hydrolysis of oxidized phospholipids generates LPC,
a powerful proinﬂammatory and atherogenic compound (22).
A recent study using vascular smooth muscle cells found that
LPC induces the expression of ALP andmineralization of cell
cultures (6). In the present study, we documented that
Figure 6 LPC Promotes Apoptosis-Mediated Mineralization of VIC Through a PKA Pathway
Mineralization of isolated VIC induced by PO4 and LPC was prevented by ZVAD-fmk, a caspase inhibitor (A), and a protein kinase A (PKA) inhibitor (PKAi) (B). (C) In isolated VIC,
LPC promoted PKA activity. (D) Mineralization of isolated VIC induced by PO4 and LPC was ampliﬁed by a treatment with forskolin. *p < 0.05 compared with Ctn; #p < 0.05
compared with LPC (C) and mineralizing medium (PO4) (A, B, D); yp < 0.05 compared with PO4 þ LPC; zp < 0.05 compared with PO4 þ forskolin. Abbreviations as in Figures 1,
3, and 4.
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467LPC-induced mineralization relied on the expression of
phosphate-related genes, including ENPP1, ALP, Pit-1, and
OPN.Whereas ENPP1 and ALP use nucleotides to generate
PPi and Pi, Pit-1 is a cell membrane Pi-transporter that plays
an important role in themineralization of the aortic valve (23).
Expression of ectonucleotidase genes, Pit-1, and OPN is
highly regulated by the concentration of extracellular phos-
phate (24). In the present study, we found that ARL67156,
which inhibits ENPP1, abrogated LPC-induced mineraliza-
tion. A complete knockdown of ENPP1 is associated with
ectopic mineralization by lowering the mineralization inhibitor
PPi to exceptionally low levels (25). For instance, the tiptoe-
walking mice with invalidation of the ENPP1 gene develop
extensive mineralization of ligament (26). On the other hand,
overexpression of ENPP1, such as during pathologic miner-
alization, promotes calciﬁcation by several mechanisms (27). In
this regard, highly-expressed ENPP1 contributes to elevate the
Pi/PPi ratio whereby mineralization is promoted (7). In addi-
tion, it should be pointed out that ALP activity was increased
following LPC treatment. ALP is a potent enzyme that
transforms PPi into Pi (28). Hence, it is possible that ENPP1
andALPwork in tandemand generate an important amount of
Pi and, in doing so, promote LPC-mediated mineralization.
Phosphate is a strong promoter of mineralization through
programmed cell death (29). LPC induced the mitochondrial-dependent apoptosis of VIC cultures. Hence, the present
ﬁndings suggest that LPC induced the expression of
phosphate-related genes, such as ENPP1, ALP, and Pit-1,
which, in turn, promoted apoptosis-mediated mineraliza-
tion of VIC cultures. Phosphate-induced expression of
ENPP1 and ALP as well as mineralization of vascular
smoothmuscle cells have been shown to be dependent on the
PKA pathway (8). In the present work, we documented that
LPC-induced mineralization was abrogated by PKA inhi-
bition, whereas a treatment with forskolin, an activator of
adenylate cyclase, exacerbated the process. Furthermore,
LPC promoted a strong increase in PKA activity in VIC.
These facts suggest that LPC induced the expression of
phosphate-generating enzymes and promoted mineraliza-
tion through a PKA-dependent pathway.
Clinical implications. There is actually no medical treat-
ment to prevent the progression of CAVD. Statins have
been used in randomized trials and have been shown to be
inefﬁcient to prevent the progression of aortic stenosis (30).
Although statins reduce the level of circulating Lp-PLA2 by
decreasing LDL concentration, they do not prevent the de
novo synthesis and secretion by macrophages (31). Hence, it
is likely that statins, although reducing the blood plasma
level of LDL, do not affect local secretion of Lp-PLA2
within the aortic valve. Accordingly, in this study, we
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468documented that Lp-PLA2 activity was elevated in stenotic
aortic valves and that tissue activity did not correlate with
blood plasma enzyme activity. These ﬁndings are in accor-
dance with a previous study (32), which showed that enzyme
activity of Lp-PLA2 in carotid endarterectomy specimen
was not associated with blood plasma activity. More
recently, a human study showed that an Lp-PLA2 mass in
the blood plasma is not increased following an inﬂammatory
stimulus. Instead, Lp-PLA2 secretion is increased by
several-fold in macrophages exposed to a lipid load.
Together, these ﬁndings suggest that Lp-PLA2 is prefer-
entially secreted by tissue macrophages rather than by
circulating leukocytes (33). Also, it should be pointed out
that the proinﬂammatory effect of Lp-PLA2 is controver-
sial. To this effect, by using platelet-activating factor and
ox-LDL as substrates, Lp-PLA2 may lower oxidative
stress (34). But, it generates lysophospholipids, which have
proinﬂammatory activity and, as shown in the present study,
promote mineralization of VIC.
Lp-PLA2 is considered a potential target in the treat-
ment of atherosclerosis. Darapladib is a potent inhibitor
of Lp-PLA2 that is under investigation in patients with
coronary artery disease and has been shown in a swine
model to decrease atherosclerotic plaque volume and to
decrease the lipid core content (5). Although CAVD shares
some features with atherosclerosis, such as lipid deposition
and inﬂammation, it is a distinct pathobiological process.
Hence, ﬁndings in atherosclerosis cannot be transposed
directly to CAVD before proper investigations have been
performed.
Study limitations. Wehave examinedCAVDwith advanced
pathological mineralization. The present study cannot neces-
sarily be transposed to nascent disease process. Nevertheless,
the present study documented several points suggesting that
Lp-PLA2 is possibly involved during the development of
CAVD.Conclusions
Lp-PLA2 is highly expressed in human CAVD. Several
lines of evidence documented in this work suggest that Lp-
PLA2 activity may contribute to the pathological minerali-
zation of the aortic valve. CAVD is a highly prevalent
condition, and there is, so far, no medical treatment to
prevent its progression. The present study gives impetus to
realize further study to document whether Lp-PLA2 could
be considered as a novel therapeutic target for CAVD.
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For a supplemental methods section, please see the online version of this
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